Downregulation of trimethyl transferase SETD2 promotes migration and proliferation of colorectal cancer cell

doi:10.16139/j.1007-9610.2020.02.011

Abstract

Abstract:

Objective: To study the effect of histone H3 lysine 36 trimethyl transferase SETD2 on colorectal cancer (CRC) cells and the tumorigenesis. Methods: The expression of SETD2 mRNA and protein decreased in CRC cell HCT116 and SW480 with transference of short hairpin RNA. There were KD group and control group. The expression of histone H3 proteins that are trimethylated on lysine 36 (H3K36me3) was detected, and the migration and proliferation capacity of two CRC cell lines were examined. The effect of SETD2 on tumor growth were observed in nude mice experiment. Results: The expression of H3K36me3 protein reduced in CRC cells following the decrease in expression of SETD2 mRNA and protein. The proliferation and migration in CRC cells increased significantly (P<0.05). H3K36me3 protein expression in tumor tissue of KD groups in nude mice experiment was much lower than that in control group by immunohistochemical staining. Tumorgenesis in KD groups occurred earlier and grew larger in size than those in control group (P<0.01). Conclusions: Downregulation of SETD2 mRNA and protein expression in CRC cells would induce the decrease of H3K36me3 protein expression in tumor tissues with migration and proliferation of tumor cells increased which suggest that SETD2 plays an important role in pathogenesis of CRC.

Key words: SETD2, Histone H3 proteins that are trimethylated on lysine 36 (H3K36me3), Colorectal cancer, Tumorgenesis

CLC Number:

CUI Ang, DING Jiazeng, CHEN Haizhen, SHEN Xiaohui, LI Chaofei, LIU Guoliang. Downregulation of trimethyl transferase SETD2 promotes migration and proliferation of colorectal cancer cell[J]. Journal of Surgery Concepts & Practice, 2020, 25(02): 139-145.

Figures/Tables 10

References 16

[1]	Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer[J]. Gastroenterology, 2000, 118(5):829-834. pmid: 10784581
[2]	Choi YJ, Oh HR, Choi MR, et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability[J]. Hum Pathol, 2014, 45(8):1674-1681. doi: 10.1016/j.humpath.2014.04.013 URL
[3]	Faber PW, Barnes GT, Srinidhi J, et al. Huntingtin interacts with a family of WW domain proteins[J]. Hum Mol Genet, 1998, 7(9):1463-1474. pmid: 9700202
[4]	Yuan W, Xie J, Long C, et al. Heterogeneous nuclear ribonucleoprotein L is a subunit of human KMT3a/Set2 complex required for H3 Lys-36 trimethylation activity in vivo[J]. J Biol Chem, 2009, 284(23):15701-15707. doi: 10.1074/jbc.M808431200 pmid: 19332550
[5]	Sun XJ, Wei J, Wu XY, et al. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase[J]. J Biol Chem, 2005, 280(42):35261-35271. doi: 10.1074/jbc.M504012200 URL
[6]	Wang S, Yuan X, Liu Y, et al. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients[J]. J Transl Med, 2019, 17(1):101. doi: 10.1186/s12967-019-1848-9 URL
[7]	Kim IK, McCutcheon JN, Rao G, et al. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer[J]. Oncogene, 2019, 38(2):180-193. doi: 10.1038/s41388-018-0429-3 URL
[8]	Chen Z, Raghoonundun C, Chen W, et al. SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion[J]. Biochem Biophys Res Commun, 2018, 498(3):579-585. doi: 10.1016/j.bbrc.2018.03.022 URL
[9]	Lowe BR, Maxham LA, Hamey JJ, et al. Histone H3 mutations: an updated view of their role in chromatin dere-gulation and cancer[J]. Cancers (Basel), 2019, 11(5):pii: E660.
[10]	Walter DM, Venancio OS, Buza EL, et al. Systematic in vivo inactivation of chromatin-regulating enzymes identifies Setd2 as a potent tumor suppressor in lung adenocarcinoma[J]. Cancer Res, 2017, 77(7):1719-1729. doi: 10.1158/0008-5472.CAN-16-2159 pmid: 28202515
[11]	Carrozza MJ, Li B, Florens L, et al. Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription[J]. Cell, 2005, 123(4):581-592. pmid: 16286007
[12]	Carvalho S, Raposo AC, Martins FB, et al. Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription[J]. Nucleic Acids Res, 2013, 41(5):2881-2893. doi: 10.1093/nar/gks1472 pmid: 23325844
[13]	Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its inte-raction with MutSa[J]. Cell, 2013, 153(3):590-600. doi: 10.1016/j.cell.2013.03.025 URL
[14]	Li L, Miao W, Huang M, et al. Integrated genomic and proteomic analyses reveal novel mechanisms of the methyltransferase SETD2 in renal cell carcinoma deve-lopment[J]. Mol Cell Proteomics, 2019, 18(3):437-447. doi: 10.1074/mcp.RA118.000957 URL
[15]	Carvalho S, Vítor AC, Sridhara SC, et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint[J]. Elife, 2014, 3:e02482. doi: 10.7554/eLife.02482 URL
[16]	Yuan H, Li N, Fu D, et al. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis[J]. J Clin Invest, 2017, 127(9):3375-3391. doi: 10.1172/JCI94292 URL